Clinicpathological features and survival of patients with AIDS related non-Hodgkin’s lymphoma
10.3760/cma.j.issn.0253-2727.2017.02.003
- VernacularTitle: 53例艾滋病相关非霍奇金淋巴瘤患者的临床特征及预后分析
- Author:
Kaiyu SUN
;
Xien GUI
;
Di DENG
;
Yong XIONG
;
Liping DENG
;
Shicheng GAO
;
Yongxi ZHANG
1
Author Information
1. Department of Infectious Disease, Zhongnan Hospital of Wuhan University. Wuhan 430071, China
- Publication Type:Journal Article
- Keywords:
Lymphoma, non-Hodgkin;
Acquired immunodeficiency syndrome;
Retrospective studies;
Survival analysis
- From:
Chinese Journal of Hematology
2017;38(2):97-101
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical characteristics, pathological features and survival of patients with AIDS related non-Hodgkin’s lymphoma (ARL) .
Methods:The clinical data of 53 ARL cases diagnosed and received care at Zhongnan hospital of Wuhan University were retrospectively studied, and 106 controls were enrolled as control group according to 1∶2 for paired cases and control. SPSS 13.0 package was used for statistical analysis. Kaplan-Meier was applied to assess the survival probability.
Results:The mean age of patients with ARL was 43 (11-67) years. Male versus female was approximately 4∶1. The median CD4+ T cell count was (146±20) /ml. The Ann Arbor clinical classification showed that 52.8% of the cases were of stage Ⅲ and Ⅳ. Approximately 54.7% of the patients had elevated serum lactate dehydrogenase (LDH) . According to international prognosis index score, 64.2% of the patients were in high risk group. Diffuse large B-cell lymphoma (DLBCL) was the predominant histological subtype. Among 53 cases, 33 cases (62.3%) received combination of anti-HIV therapy and anti-NHL (CHOP) chemotherapy regimen, 8 cases (15.1%) only received anti-HIV therapy, and 12 cases (22.6%) asked for alleviative treatment. Median survival time was (6.0±1.3) months for ARL cases versus (48.0±10.0) months for controls (P<0.05) . After eliminating cases who did not receive anti-lymphoma treatment, ARL cases showed a lower 1-year OS rates than control group (60.6% versus 83.0%) , but no difference about 2-, 3- and 5-year OS rates (53.5% versus 60.5%, 48.1% versus 45.9%, and 39.1% versus 27.5%, respectively) .
Conclusions:ARL is more common in young adults; one-year mortality rate is high. Anti-HIV therapy combined with anti-NHL therapy could significantly improve the prognosis of ARL patients. CHOP regimen may be more suitable for ARL patients.
